Pronounced induction of endoplasmic reticulum stress and tumor suppression by surfactant-free poly(lactic-co-glycolic acid) nanoparticles via modulation of the PI3K signaling pathway

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2689-2706

  Hou, Chia Cheng ^a   Tsai, Tsung Lin ^a   Su, Wen Pin ^a   Hsieh, Hsing Pang ^b   Yeh, Chen Sheng ^a   Shieh, Dar Bin ^a   Su, Wu Chou ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

AKT; Endoplasmic reticulum stress; LY294002; Surfactant free poly(lactic co glycolic acid)

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; NANOPARTICLE; PHOSPHATIDYLINOSITOL 3 KINASE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ENDOPLASMIC RETICULUM STRESS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ULTRAVIOLET SPECTROPHOTOMETRY; WESTERN BLOTTING;

AKT; ENDOPLASMIC RETICULUM STRESS; LY294002; SURFACTANT-FREE POLY(LACTIC-CO-GLYCOLIC ACID);

ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, NUDE; MORPHOLINES; NANOPARTICLES; PHOSPHATIDYLINOSITOL 3-KINASES; POLYGLYCOLIC ACID; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880810535     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S47208     Document Type: Article

References (38)

1. Liu P, Cheng H, Roberts T.M, Zhao J.J. Targeting the phosphoinosit-ide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8): 627-644.
2. Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol. 2010;21(4):683-691.
3. Steelman L.S, Stadelman K.M, Chappell W.H, et al. Akt as a therapeutic target in cancer. Expert Opin Ther Targets. 2008;12(9):1139-1165.
4. Hennessy B.T, Smith D.L, Ram P.T, Lu Y, Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988-1004.
5. Yuan T.L, Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27(41):5497-5510.
6. Walker E.H, Pacold M.E, Perisic O, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000;6(4): 909-919.
7. Hill M.M, Hemmings B.A. Inhibition of protein kinase B/Akt implications for cancer therapy. Pharmacol Ther. 2002;93(2-3): 243-251.
8. Brognard J, Clark A.S, Ni Y, Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61(10):3986-3997.
9. Krystal G.W, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3- kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther. 2002;1(11):913-922.
10. LoPiccolo J, Blumenthal G.M, Bernstein W.B, Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11(1-2):32-50.
11. Hu L, Hofmann J, Lu Y, Mills G.B, Jaffe R.B. Inhibition of phosphati-dylinositol 3-kinase increases effcacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002;62(4):1087-1092.
12. Hu L, Zaloudek C, Mills G.B, Gray J, Jaffe R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res. 2000;6(3):880-886.
13. Jiang H, Fan D, Zhou G, Li X, Deng H. Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J Exp Clin Cancer Res. 2010;29:34.
14. Marone R, Cmiljanovic V, Giese B, Wymann M.P. Targeting phospho-inositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2008;1784(1):159-185.
15. Soppimath K.S, Aminabhavi T.M, Kulkarni A.R, Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1-2):1-20.
16. West J, Halas N.J. Applications of nanotechnology to biotechnology commentary. Curr Opin Biotechnol. 2000;11(2):215-217.
17. Hogemann D, Ntziachristos V, Josephson L, Weissleder R. High throughput magnetic resonance imaging for evaluating targeted nano-particle probes. Bioconjug Chem. 2002;13(1):116-121.
18. Tkachenko A.G, Xie H, Liu Y, et al. Cellular trajectories of peptide-modifed gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem. 2004;15(3): 482-490.
19. Parveen S, Sahoo S.K. Polymeric nanoparticles for cancer therapy. J Drug Target. 2008;16(2):108-123.
20. Di Toro R, Betti V, Spampinato S. Biocompatibility and integrin-mediated adhesion of human osteoblasts to poly(DL-lactide-co-glycolide) copolymers. Eur J Pharm Sci. 2004;21(2-3):161-169.
21. Danhier F, Ansorena E, Silva J.M., Coco R., Le Breton A, Preat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release. 2012;161(2):505-522.
22. Esmaeili F, Ghahremani M.H, Esmaeili B, Khoshayand M.R, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm. 2008;349(1-2):249-255.
23. Mundargi R.C, Babu V.R, Rangaswamy V, Patel P, Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125(3):193-209.
24. Harfouche R, Basu S, Soni S, Hentschel DM, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis. 2009;12(4): 325-338.
25. Sahoo S.K, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002;82(1):105-114
26. Cheng F.Y., Wang S.P., Su C.H., et al. Stabilizer-free poly(lactide-co- glycolide) nanoparticles for multimodal biomedical probes. Biomaterials. 2008;29(13):2104-2112.
27. Kuo W.S, Ku Y.C, Sei, H.T, Cheng F.Y, Yeh C.S. Paclitaxel-loaded stabilizer-free poly(D,L-lactide-co-glycolide) nanoparticles conjugated with quantum dots for reversion of anti-cancer drug resistance and cancer cellular imaging. Chin Chem Soc. 2009;56(5):923-934.
28. Yeh H.H, Lai W.W, Chen H.H, Liu H.S, Su W.C. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene. 2006;25(31):4300-4309.
29. Schafer Z.T, Kornbluth S. The apoptosome: physiological, developmental, and pathological modes of regulation. Dev Cell. 2006;10(5): 549-561.
30. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004;11(4):381-389.
31. Lee H, Park M.T, Choi B.H, et al. Endoplasmic reticulum stress-induced JNK activation is a critical event leading to mitochondria-mediated cell death caused by beta-lapachone treatment. PLoS One. 2011;6(6): e21533.
32. Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40(2):280-293.
33. Sinha R, Kim G.J, Nie S, Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5(8):1909-1917.
34. Moghimi S.M, Hunter A.C, Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311-330.
35. Torche A.M, Le Corre P, Albina E, Jestin A, Le Verge R. PLGA microspheres phagocytosis by pig alveolar macrophages: infuence of poly(vinyl alcohol) concentration, nature of loaded-protein and copolymer nature. J Drug Target. 2000;7(5):343-354.
36. Prabha S, Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res. 2004;21(2): 354-364.
37. Brognard J, Clark A.S, Ni Y, Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61(10):3986-3997.
38. Paulo C.S, Pires das Neves R, Ferreira L.S. Nanoparticles for intracellular-targeted drug delivery. Nanotechnology. 2011;22(49): 494002.